Diabetic drugs

Option A: Hypoglycaemia is the most common adverse reaction to insulin therapy, resulting from an imbalance between insulin administration and carbohydrate intake or physical activity. It can lead to symptoms such as sweating, shaking, confusion, and in severe cases, loss of consciousness or seizures, necessitating prompt recognition and management.

Option B: Lipodystrophy occurs due to repeated insulin injections in the same site, leading to localized fat atrophy or hypertrophy, but it is less common than hypoglycaemia.

Option C: Urticaria is an allergic reaction that can occur with insulin use, but it is not a frequent adverse effect compared to hypoglycaemia.

Option D: Angioedema, a more serious allergic reaction, can occur with insulin but is rare and not the most common adverse reaction associated with its use.

Takeaways: Hypoglycaemia is the primary adverse effect of insulin therapy, highlighting the importance of monitoring blood glucose levels and educating patients on recognizing symptoms of low blood sugar, which requires patient education on insulin management to prevent complications.

Option B: Insulin requirement more than 40 U/day indicates a higher level of insulin resistance or beta-cell dysfunction, which often necessitates insulin therapy rather than oral hypoglycemics. This feature disfavors the use of oral agents as they may not adequately control blood glucose levels in such cases.

Option A: Age at onset of disease over 40 years does not inherently disfavor oral hypoglycemics, as many patients diagnosed later in life can still effectively manage diabetes with these medications.

Option C: Fasting blood sugar level between 100-200 mg/dl suggests mild to moderate hyperglycemia, which can often be managed with oral hypoglycemics, making this option favorable rather than unfavorable.

Option D: Associated obesity is commonly linked to type 2 diabetes and does not disfavor the use of oral hypoglycemics; in fact, certain oral agents can promote weight loss or weight neutrality, making them suitable for obese patients.

Takeaways: The requirement for more than 40 U/day of insulin indicates significant insulin resistance, which typically necessitates insulin therapy rather than oral hypoglycemics, as outlined in clinical guidelines for diabetes management.

Option A: The hypoglycaemic action of sulfonylureas is likely to be attenuated by the concurrent use of hydrochlorothiazide, as thiazide diuretics can increase blood glucose levels by promoting insulin resistance and reducing insulin secretion. This interaction diminishes the effectiveness of sulfonylureas in lowering blood glucose levels.

Option B: Propranolol can mask hypoglycaemic symptoms but does not directly attenuate the action of sulfonylureas. It may affect glucose metabolism but does not negate the drug's efficacy.

Option C: Chloramphenicol does not have a significant interaction with sulfonylureas that would attenuate their hypoglycaemic effect. Its primary concern is related to potential bone marrow suppression rather than glucose regulation.

Option D: Aspirin can enhance the hypoglycaemic effect of sulfonylureas by increasing insulin sensitivity. It does not attenuate the action of these medications.

Takeaways: Understanding the interactions between medications, such as how hydrochlorothiazide can reduce the effectiveness of sulfonylureas, is crucial for effective diabetes management and requires patient education on medication interactions to ensure optimal therapeutic outcomes.

Option A: Metformin does not cause hypoglycemia even in large doses, as its primary mechanism is to decrease hepatic glucose production and improve insulin sensitivity rather than stimulate insulin release. This characteristic makes it a safe option for managing blood glucose levels without the risk of hypoglycemia, which is particularly beneficial in patients with type 2 diabetes.

Option B: Metformin can be safely combined with glipizide, as they work through different mechanisms to control blood glucose levels. Metformin enhances insulin sensitivity, while glipizide stimulates insulin secretion from the pancreas.

Option C: Metformin is not contraindicated in obese patients with non-insulin-dependent diabetes mellitus (NIDDM); in fact, it is often recommended for this population due to its weight-neutral effects and potential for weight loss.

Option D: Metformin does not cause the release of insulin from the pancreas; instead, it primarily works by reducing glucose production in the liver and increasing insulin sensitivity in peripheral tissues.

Takeaways: Metformin is a cornerstone in managing type 2 diabetes as it does not induce hypoglycemia, making it a preferred choice for many patients. Understanding its mechanisms and safety profile is essential for effective diabetes management, which requires patient education on medication use and side effects.

Option A: Administration of prednisolone can vitiate glycaemia control in patients with diabetes mellitus maintained on insulin therapy due to its glucocorticoid effects, which can increase insulin resistance and elevate blood glucose levels. This necessitates careful monitoring and potential adjustment of insulin dosages to maintain glycaemic control.

Option B: Prazosin primarily acts as an alpha-1 adrenergic antagonist and does not significantly influence glucose metabolism or insulin sensitivity, making it less likely to affect glycaemia control in diabetic patients.

Option C: Paracetamol, an analgesic and antipyretic, does not have a direct impact on glucose metabolism or insulin action, thus it does not interfere with glycaemia control in patients on insulin therapy.

Option D: Phenytoin, an anticonvulsant, can affect glucose levels but typically does not have a significant impact on glycaemia control in the context of insulin therapy compared to glucocorticoids like prednisolone.

Takeaways: Understanding the impact of medications like prednisolone on glycaemia control is crucial for managing diabetes effectively, as it can lead to increased insulin resistance; therefore, clinicians must adjust insulin therapy accordingly to maintain optimal blood glucose levels, which requires patient education on medication interactions to ensure safe management.

Option A: Human insulins are not obtained from cadaver pancreas, as this method is outdated and poses significant safety and ethical concerns. Modern insulin production relies on recombinant DNA technology, ensuring a safer and more reliable source of insulin for patients.

Option B: Proinsulin recombinant bacterial methods are a standard practice in insulin production, utilizing genetically modified bacteria to produce insulin precursors that are later processed into active insulin.

Option C: Precursor yeast recombinant techniques are also valid, as yeast can be genetically engineered to produce insulin, providing a viable and effective source for human insulin.

Option D: Enzyme modification of pork insulin is a legitimate method, as it allows for the alteration of animal-derived insulin to make it more similar to human insulin, enhancing its efficacy and safety.

Takeaways: Human insulin is primarily produced through recombinant DNA technology, utilizing bacteria or yeast, while cadaver pancreas is not a viable source due to ethical and safety issues. Understanding these production methods is crucial for safe insulin administration and patient education on diabetes management, which requires knowledge of insulin types and their sources.